These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 17878479)

  • 1. Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer.
    Heymach JV; Johnson BE; Prager D; Csada E; Roubec J; Pesek M; Spásová I; Belani CP; Bodrogi I; Gadgeel S; Kennedy SJ; Hou J; Herbst RS
    J Clin Oncol; 2007 Sep; 25(27):4270-7. PubMed ID: 17878479
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial.
    Herbst RS; Sun Y; Eberhardt WE; Germonpré P; Saijo N; Zhou C; Wang J; Li L; Kabbinavar F; Ichinose Y; Qin S; Zhang L; Biesma B; Heymach JV; Langmuir P; Kennedy SJ; Tada H; Johnson BE
    Lancet Oncol; 2010 Jul; 11(7):619-26. PubMed ID: 20570559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer.
    Choueiri TK; Ross RW; Jacobus S; Vaishampayan U; Yu EY; Quinn DI; Hahn NM; Hutson TE; Sonpavde G; Morrissey SC; Buckle GC; Kim WY; Petrylak DP; Ryan CW; Eisenberger MA; Mortazavi A; Bubley GJ; Taplin ME; Rosenberg JE; Kantoff PW
    J Clin Oncol; 2012 Feb; 30(5):507-12. PubMed ID: 22184381
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial.
    de Boer RH; Arrieta Ó; Yang CH; Gottfried M; Chan V; Raats J; de Marinis F; Abratt RP; Wolf J; Blackhall FH; Langmuir P; Milenkova T; Read J; Vansteenkiste JF
    J Clin Oncol; 2011 Mar; 29(8):1067-74. PubMed ID: 21282537
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions.
    Morabito A; Piccirillo MC; Falasconi F; De Feo G; Del Giudice A; Bryce J; Di Maio M; De Maio E; Normanno N; Perrone F
    Oncologist; 2009 Apr; 14(4):378-90. PubMed ID: 19349511
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EGFR biomarkers predict benefit from vandetanib in combination with docetaxel in a randomized phase III study of second-line treatment of patients with advanced non-small cell lung cancer.
    Heymach JV; Lockwood SJ; Herbst RS; Johnson BE; Ryan AJ
    Ann Oncol; 2014 Oct; 25(10):1941-1948. PubMed ID: 25057173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: results from a two-part, double-blind, randomized phase ii study.
    Natale RB; Bodkin D; Govindan R; Sleckman BG; Rizvi NA; Capó A; Germonpré P; Eberhardt WE; Stockman PK; Kennedy SJ; Ranson M
    J Clin Oncol; 2009 May; 27(15):2523-9. PubMed ID: 19332730
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer.
    Heymach JV; Paz-Ares L; De Braud F; Sebastian M; Stewart DJ; Eberhardt WE; Ranade AA; Cohen G; Trigo JM; Sandler AB; Bonomi PD; Herbst RS; Krebs AD; Vasselli J; Johnson BE
    J Clin Oncol; 2008 Nov; 26(33):5407-15. PubMed ID: 18936474
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vandetanib with docetaxel as second-line treatment for advanced breast cancer: a double-blind, placebo-controlled, randomized Phase II study.
    Boér K; Láng I; Llombart-Cussac A; Andreasson I; Vivanco GL; Sanders N; Pover GM; Murray E
    Invest New Drugs; 2012 Apr; 30(2):681-7. PubMed ID: 20830502
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized, double-blind, placebo-controlled phase II study of vandetanib plus docetaxel/prednisolone in patients with hormone-refractory prostate cancer.
    Horti J; Widmark A; Stenzl A; Federico MH; Abratt RP; Sanders N; Pover GM; Bodrogi I
    Cancer Biother Radiopharm; 2009 Apr; 24(2):175-80. PubMed ID: 19409038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized, phase II study of vandetanib maintenance for advanced or metastatic non-small-cell lung cancer following first-line platinum-doublet chemotherapy.
    Ahn JS; Lee KH; Sun JM; Park K; Kang ES; Cho EK; Lee DH; Kim SW; Lee GW; Kang JH; Lee JS; Lee JW; Ahn MJ
    Lung Cancer; 2013 Dec; 82(3):455-60. PubMed ID: 24075125
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of vandetanib or placebo in small-cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy: National Cancer Institute of Canada Clinical Trials Group Study BR.20.
    Arnold AM; Seymour L; Smylie M; Ding K; Ung Y; Findlay B; Lee CW; Djurfeldt M; Whitehead M; Ellis P; Goss G; Chan A; Meharchand J; Alam Y; Gregg R; Butts C; Langmuir P; Shepherd F;
    J Clin Oncol; 2007 Sep; 25(27):4278-84. PubMed ID: 17878480
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial.
    Reck M; Kaiser R; Mellemgaard A; Douillard JY; Orlov S; Krzakowski M; von Pawel J; Gottfried M; Bondarenko I; Liao M; Gann CN; Barrueco J; Gaschler-Markefski B; Novello S;
    Lancet Oncol; 2014 Feb; 15(2):143-55. PubMed ID: 24411639
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomised phase II study of docetaxel plus vandetanib versus docetaxel followed by vandetanib in patients with persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: SWOG S0904.
    Coleman RL; Moon J; Sood AK; Hu W; Delmore JE; Bonebrake AJ; Anderson GL; Chambers SK; Markman M
    Eur J Cancer; 2014 Jun; 50(9):1638-48. PubMed ID: 24709487
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Double-blind, placebo-controlled, randomized phase 2 study of the proapoptotic agent AT-101 plus docetaxel, in second-line non-small cell lung cancer.
    Ready N; Karaseva NA; Orlov SV; Luft AV; Popovych O; Holmlund JT; Wood BA; Leopold L
    J Thorac Oncol; 2011 Apr; 6(4):781-5. PubMed ID: 21289522
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vandetanib Versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind phase III trial (ZEPHYR).
    Lee JS; Hirsh V; Park K; Qin S; Blajman CR; Perng RP; Chen YM; Emerson L; Langmuir P; Manegold C
    J Clin Oncol; 2012 Apr; 30(10):1114-21. PubMed ID: 22370318
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized, double-blind, phase II study of ramucirumab plus docetaxel vs placebo plus docetaxel in Japanese patients with stage IV non-small cell lung cancer after disease progression on platinum-based therapy.
    Yoh K; Hosomi Y; Kasahara K; Yamada K; Takahashi T; Yamamoto N; Nishio M; Ohe Y; Koue T; Nakamura T; Enatsu S; Lee P; Ferry D; Tamura T; Nakagawa K
    Lung Cancer; 2016 Sep; 99():186-93. PubMed ID: 27565938
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized, double-blind, phase IIa dose-finding study of Vandetanib (ZD6474) in Japanese patients with non-small cell lung cancer.
    Kiura K; Nakagawa K; Shinkai T; Eguchi K; Ohe Y; Yamamoto N; Tsuboi M; Yokota S; Seto T; Jiang H; Nishio K; Saijo N; Fukuoka M
    J Thorac Oncol; 2008 Apr; 3(4):386-93. PubMed ID: 18379357
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vandetanib plus chemotherapy for induction followed by vandetanib or placebo as maintenance for patients with advanced non-small-cell lung cancer: a randomized phase 2 PrECOG study (PrE0501).
    Aisner J; Manola JB; Dakhil SR; Stella PJ; Sovak MA; Schiller JH
    J Thorac Oncol; 2013 Aug; 8(8):1075-83. PubMed ID: 23689430
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II randomized study of vandetanib plus gemcitabine or gemcitabine plus placebo as first-line treatment of advanced non-small-cell lung cancer in elderly patients.
    Gridelli C; Novello S; Zilembo N; Luciani A; Favaretto AG; De Marinis F; Genestreti G; Crinò L; Grossi F; Caffo O; Ferraù F; Cruciani G; Brandes AA; Galetta D; Barni S; Fasola G; Cerea G; Ferrari S; Iannacone C; Ciardiello F
    J Thorac Oncol; 2014 May; 9(5):733-7. PubMed ID: 24722160
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.